乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

EASL

<乌鸦传媒>'A New Hope' for Rare, Deadly Liver Disease

Small fazirsiran trial sees fibrosis regressions for liver disease associated with AAT deficiency

<乌鸦传媒>Mixed Bag for Semaglutide in NASH-Related Compensated Cirrhosis

Randomized trial showed improvements in cardiometabolic markers, but not liver fibrosis

<乌鸦传媒>Liver Cirrhosis Tied to Elevated Risk for Stroke

37% higher risk observed in large German study

<乌鸦传媒>Bulevirtide's Effect Sustained in Difficult-to-Treat Hepatitis D

Nearly half of patients at week 48 had virological and biochemical response

<乌鸦传媒>German Study Warns of Increasing Acute Hep C Reinfections in MSM

14% of patients experienced a reinfection over the past decade

<乌鸦传媒>Early Liver Disease Detection Linked to Subsequent Lifestyle Improvements

Danish study shows fibrosis screening associated with improved diet, alcohol use, and exercise

<乌鸦传媒>Novel Liver Assist Device Safe for Patients With Cirrhosis

Small preliminary trial also shows hints of promising clinical results

<乌鸦传媒>Resmetirom Delivers Promising Outcomes in NASH Without Invasive Follow-Up

Real-world study also identifies noninvasive markers for treatment response

<乌鸦传媒>Food Insecurity Tied to More Liver Disease Deaths

Social determinants of health play a key role, study found

<乌鸦传媒>Dads With Obesity Mostly Cleared in Their Children's NAFLD

U.K. study confirms it's mainly mom's fault

<乌鸦传媒>Adding PD-1 Inhibitor Shows Promise in Potentially Resectable HCC

"Safe and successful conversion therapy" with hepatic arterial infusion chemo plus sintilimab

<乌鸦传媒>Tenofovir Treatment Lessened Risk of Severe COVID Infection in HBV

But expert questions conclusion of small study from Spain

<乌鸦传媒>Bulevirtide Shows Promise in Tough-to-Treat Hepatitis D

Significant responses seen with novel agent for "devil" disease

<乌鸦传媒>Big Jump in Monthly Average Hospital Admission for Alcoholic Hepatitis Post-Pandemic

Long-term impact of alcohol uptake on liver health during COVID-19 crisis remains unknown

<乌鸦传媒>Liver Fibrosis Linked to Lower Response to COVID Vaccine

Third dose may be needed in this population as well as some transplant patients, says researcher

<乌鸦传媒>The Murky Post-Pandemic Future of Hepatitis C Elimination in the U.S.

Modeling study demonstrates need to rebound or risk losing progress

<乌鸦传媒>Rise in Alcohol Dependence Seen During Pandemic

AUD in U.K. study tied to worse COVID outcomes and more mental health problems as well

<乌鸦传媒>Liver Disease Tied to Increased Risk of Death From Severe COVID

French study of hospitalized patients also saw an increased risk of mechanical ventilation

<乌鸦传媒>Core Protein Inhibitor: A Key to Eventual HBV Cure?

Entecavir plus novel core protein inhibitor led to dramatic declines in hepatitis B DNA, RNA

<乌鸦传媒>Promising Results with Givosiran in Acute Hepatic Porphyrias

Patients on novel agent showed significant urinary ALA reduction versus placebo

<乌鸦传媒>Combo Tx With 'Entry Inhibitor' Latest Hope in Treating Hep D

Myrcludex B and interferon shows promise in HBV/HDV co-infection

<乌鸦传媒>Drug Shows Promise in Treating NASH

Obeticholic acid improves fibrosis in interim phase III data

<乌鸦传媒>Cirrhosis 'Turning Point' in Fatty Liver Progression

Most patients identified with decompensated event, real-world study finds

<乌鸦传媒>Cure for Hepatitis B Pushed

Disease affecting 257 million people needs better treatment

<乌鸦传媒>Novel Non-Bile FXR Agonist Promising in PBC Patients

Phase II trial interim analysis found dose-dependent response, good safety profile

<乌鸦传媒>Biliary Fibrosis Stabilized with Obeticholic Acid

Biopsy study supports anti-fibrosis properties of agent

<乌鸦传媒>Hepatitis C Treatments Reduce Transplants

Therapies also appear to reduce liver-related mortality

<乌鸦传媒>Europe Gets Updated HCV Tx Guidelines

EASL panel touts 'ease of use' of direct-acting antivirals

<乌鸦传媒>SIRT + Sorafenib = No Survival Bump in Liver Cancer

But clinical benefits suggested in certain patients with less severe disease

<乌鸦传媒>Lipid-Lowering Drug Offers New Hope in PBC

First gold standard trial confirms benefits of bezafibrate

<乌鸦传媒>Climate Tied to Alcohol-Related Liver Disease

Is alcoholic cirrhosis a product of cold, gray weather?

<乌鸦传媒>Liver Cancer Tx with Radioactive Beads Yields Mixed Results

No survival benefit but quality of life better

<乌鸦传媒>Gum Disease, Mortality Linked in Cirrhosis

Severity of periodontitis increases risk

<乌鸦传媒>Simple, Short HCV Regimen Has High Cure Rate

LONDON -- A single pill once a day for 8 weeks is enough to cure more than 90% of hepatitis C virus patients with relatively uncomplicated disease, a researcher said.

<乌鸦传媒>Fatty Liver Tied to Diabetes, Atherosclerosis

LONDON -- Non-alcoholic fatty liver disease (NAFLD) is an independent predictor of both type 2 diabetes and carotid atherosclerosis, according to two studies presented here at the annual meeting of the European Association for the Study of the Liver.